Adcy5 Protein — Adenylate Cyclase 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Adenylate Cyclase 5 |
|---|---|
| Gene | [ADCY5](/genes/adcy5) |
| UniProt ID | [O95622](https://www.uniprot.org/uniprot/O95622) |
| Protein Size | 1,224 amino acids (~138 kDa) |
| Subcellular Localization | Plasma membrane; intracellular compartments |
| Protein Family | Adenylyl cyclase family (ADCY) |
| PDB Structures | [1CJK](https://www.ebi.ac.uk/pdbe/search/pdb/1CJK), [1CJM](https://www.ebi.ac.uk/pdbe/search/pdb/1CJK) |
Adenylate Cyclase 5 (ADCY5) is a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP), a crucial second messenger involved in numerous signaling pathways in the brain. ADCY5 is particularly important in dopaminergic signaling and motor control.
ADCY5 is a large transmembrane enzyme with complex domain organization:
The protein has a "M-shaped" structure with transmembrane helices forming the base and cytoplasmic catalytic domains forming the arms.
ADCY5 performs essential signaling functions:
cAMP Production: Catalyzes ATP → cAMP, the central second messenger in G-protein-coupled receptor (GPCR) signaling.
Dopaminergic Signaling: ADCY5 is highly expressed in striatal medium spiny neurons where it couples D1 dopamine receptor signaling to cAMP production[1].
Motor Control: cAMP production in basal ganglia regulates movement initiation and motor learning.
Synaptic Plasticity: cAMP modulates synaptic strength and long-term potentiation.
Gene Expression: cAMP activates PKA and CREB, regulating transcription of plasticity-related genes.
Dominant ADCY5 mutations cause the most common form of genetic dystonia, characterized by rapid, involuntary muscle contractions and abnormal postures[2]. Mutations lead to:
ADCY5 mutations cause a distinct syndrome with paroxysmal dyskinesias and facial myokymia.
ADCY5 expression is altered in AD brains:
Dysregulated cAMP signaling in dopaminergic neurons is implicated in PD pathogenesis, and ADCY5 may be relevant to L-DOPA-induced dyskinesias.
ADCY5 and its downstream signaling are therapeutic targets:
ADCY5 interacts with:
The study of Adcy5 Protein — Adenylate Cyclase 5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.